for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
completion around



The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).

Official Title

A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma


Relapsed and/or Refractory Multiple Myeloma, Dual Targeting, BCMAxGPRC5D, GPRC5DxBCMA, BMS-986453, CAR T, CART, Multiple Myeloma, Relapsed and/or Refractory, Plasma Cell Neoplasms, Cyclophosphamide, Fludarabine, Administration of BMS-986453


You can join if…

Open to people ages 18 years and up

  • Participants must have a diagnosis of multiple myeloma with relapsed and/or refractory disease.
  • Participants must have confirmed progressive disease on or within 12 months (measured from the last dose) of completing treatment with the last anti-myeloma treatment regimen before study entry.
  • Participants in Part A and Part B Cohort 1 must have received at least 3 prior anti-myeloma treatment regimens, including a proteasome inhibitor and immunomodulatory agent.
  • Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Participants must have adequate organ function.

You CAN'T join if...

  • Participants must not have any known active or history of central nervous system (CNS) involvement of multiple myeloma.
  • Participants must not have active or history of plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome, or clinically significant amyloidosis.
  • Participants must not have a history or presence of clinically significant CNS pathology such as seizure disorder, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, or cerebellar disease, or presence of clinically active psychosis.

Other protocol-defined inclusion/exclusion criteria apply


  • Local Institution - 0011 not yet accepting patients
    San Francisco California 94143 United States
  • Local Institution - 0006 not yet accepting patients
    Stanford California 94305 United States
  • Swedish Medical Center accepting new patients
    Seattle Washington 98104 United States
  • Colorado Blood Cancer Institute accepting new patients
    Denver Colorado 80218 United States


accepting new patients at some sites,
but this study is not currently recruiting here
Start Date
Completion Date
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
BMS Clinical Trial Information BMS Clinical Trial Patient Recruiting
Phase 1 Multiple Myeloma Research Study
Study Type
Expecting 130 study participants
Last Updated